Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Held-Warmkessel J. Taming three high-risk chemotherapy complications. Nursing. 2011 Nov;41(11):30-7.   PMCID: not NIH funded
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan;79(1):65-70.   PMCID: PMC3339153
von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat Rev. 2011 Jun;37(4):291-9.   PMCID: not NIH funded
Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC cancer. 2010 Jan;10:34.   PMCID: PMC2829496
Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochemical pharmacology. 2010 Sep;80(5):762-70.   PMCID: PMC2897922
Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU international. 2010 Jul;106(2):218-23.   PMCID: PMC2906619
Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR. Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys. 2009 Jul;74(3):689-94.   PMCID: PMC2720600
Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, American Society of Clinical O. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009 Aug 10;27(23):3868-74.
Pimkina J, Murphy ME. ARF, autophagy and tumor suppression. Autophagy. 2009 Apr;5(3):397-9.   PMCID: PMC2667648
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-91.   PMCID: PMC2875773
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008 Jan;6 Suppl 4:S1-S25; quiz S26-S27.
Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. American journal of clinical pathology. 2008 Oct;130(4):604-12.
Held-Warmkessel J. Caring for a patient with metastatic prostate cancer. Nursing. 2008 Jun;38(6):52-6.
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, National Comprehensive Cancer N. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul;6(6):594-622.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?. Clinical lung cancer. 2008 Mar;9(2):85-91.
Mehra R, Cohen RB. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi.   PMCID: PMC2659655
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents therapeutic use drug therapy Female Male pathology Middle Aged methods therapy adverse effects Aged Adult pharmacology Monoclonal Antibodies Neoplasms 80 and over Aged epidemiology Patient Education as Topic surgery Drug Delivery Systems Retrospective Studies United States Clinical Trials as Topic Lung Neoplasms diagnosis chemically induced Neoplasm Metastasis Combined Modality Therapy mortality Non-Small-Cell Lung Carcinoma Pyrimidines trends administration & dosage Piperazines Antineoplastic Combined Chemotherapy Protocols Neoplasm Staging Nurse's Role Protein-Tyrosine Kinases radiotherapy administration & Radiotherapy Dosage Treatment Outcome antagonists & inhibitors dosage Time Factors metabolism economics genetics pharmacokinetics blood Follow-Up Studies Oncologic Nursing Drug Monitoring Breast Neoplasms Intensity-Modulated Radiotherapy Gastrointestinal Stromal Tumors Adolescent Nursing Assessment secondary Cost-Benefit Analysis Disease-Free Survival nursing Fever Drug Eruptions Age Factors Drug Industry ADP-Ribosylation Factor 1 Salivary Gland Neoplasms RNA Communication Life Expectancy Acute Disease Monte Carlo Method Polyglutamic Acid Local Neoplasm Recurrence Radiodermatitis Oligonucleotide Array Sequence Analysis Immunohistochemistry Paronychia Autopsy Medical Education-Continuing p53 Genes Prostatectomy Prostatic Neoplasms Young Adult histology Drug Interactions Biological Models Pyrroles Palliative Care Paclitaxel Proteomics Reverse Transcriptase Polymerase Chain Reaction etiology Autophagy Gene Silencing Insurance Coverage Drug Carriers drug effects Prednisone Social Support Psychological Adaptation Physician-Patient Relations Neoplastic Gene Expression Regulation Radiotherapy Markov Chains Cell Survival Lymph Nodes Kidney Neoplasms Liposomes Protein Kinase Inhibitors Neutropenia Patient Care Team anatomy & Neoplasm Transplantation Androgen Antagonists Health Insurance Hodgkin Disease Mesothelioma Hypertension Gonadotropin-Releasing Hormone Monoclonal Antibodies-Murine-Derived Photons Evidence-Based Medicine Carboplatin Nephrectomy Treatment Failure Quality of Life physiology Drug Dose-Response Relationship Squamous Cell Carcinoma Tumor Suppressor Proteins Linear Models Drug Costs Risk Factors Immunotherapy Epidemiologic Methods instrumentation Doxorubicin Vincristine Forecasting Biological Tumor Markers B-Lymphocytes Interdisciplinary Communication utilization Peritoneal Neoplasms Kidney Diseases Survival Rate Medical Oncology Gastrostomy
Last updated on Wednesday, February 05, 2020